-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that on July 1, 2026, the company's holding subsidiary Jushi Biotech signed a “Cooperation, Choice and Authorization Agreement” with AstraZeneca to develop strategic cooperation with AstraZeneca in the field of novel low-interfering nucleic acid candidates to develop novel low-interfering molecular nucleic acid candidates for extra-hepatic delivery. According to the agreement, Jushi Biotech has received a down payment of 30 million US dollars from AstraZeneca on August 12, 2026 (the actual payment amount is subject to deduction of bank charges).

Zhitongcaijing·08/12/2026 10:57:13
Listen to the news
Zhitong Finance App News, Shiyao Innovation (300765.SZ) announced that on July 1, 2026, the company's holding subsidiary Jushi Biotech signed a “Cooperation, Choice and Authorization Agreement” with AstraZeneca to develop strategic cooperation with AstraZeneca in the field of novel low-interfering nucleic acid candidates to develop novel low-interfering molecular nucleic acid candidates for extra-hepatic delivery. According to the agreement, Jushi Biotech has received a down payment of 30 million US dollars from AstraZeneca on August 12, 2026 (the actual payment amount is subject to deduction of bank charges).